![SIRTURO® (bedaquiline) Development and Launch](https://www.amrindustryalliance.org/wp-content/uploads/2017/12/GettyImages-521811051-1080x675.jpg)
![SIRTURO® (bedaquiline) Development and Launch](https://www.amrindustryalliance.org/wp-content/uploads/2017/12/GettyImages-521811051-1080x675.jpg)
![BEAM Alliance – Guidelines as to how antibacterial R&D could be revived and proposes specific support for SME-driven innovation in the AMR field.](https://www.amrindustryalliance.org/wp-content/uploads/2017/12/GettyImages-738786269-1080x675.jpg)
BEAM Alliance – Guidelines as to how antibacterial R&D could be revived and proposes specific support for SME-driven innovation in the AMR field.
![AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria](https://www.amrindustryalliance.org/wp-content/uploads/2017/12/GettyImages-525440711-1080x675.jpg)
AiCuris Initiates Clinical Development of AIC499, a Novel Resistance-Breaking Antibiotic against a Broad Range of MDR Gram-Negative Bacteria
![BD – “Resistance Fighter” Awareness and Mobilization Campaign](https://www.amrindustryalliance.org/wp-content/uploads/2017/12/GettyImages-458004639-1080x675.jpg)
BD – “Resistance Fighter” Awareness and Mobilization Campaign
![iNtRON- N-Rephasin® SAL200 (Tonabacase)](https://www.amrindustryalliance.org/wp-content/uploads/2017/12/GettyImages-697554855-1080x675.jpg)